Advertisement

Drug-Induced Headache — Does a Critical Dosage Exist?

  • E. Scholz
  • H.-C. Diener
  • S. Geiselhart
Part of the Advances in Applied Neurological Sciences book series (NEUROLOGICAL, volume 5)

Abstract

Although the clinical problem of chronic daily headache induced by chronic intake of ergotamine tartrate and/or analgesics is known to clinicians (Lippman 1955; Horton et al. 1963; Rowsell et al. 1973; Wainscott et al. 1974; Andersson 1975; Ala-Hurula et al. 1982; Kudrow 1982; Saper 1983; Dichgans et al. 1984), no information is as yet available about the dosages of different drugs necessary to provoke this response. The patients’ histories show a gradual increase in frequency and dose of drug intake, eventually ending in daily administration of high dosages. It is unknown whether the daily intake itself or the drug dosage plays the crucial role.

Keywords

Salicylic Acid Daily Intake Migraine Patient Chronic Headache Migraine Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aellig WH (1982) Agonists and antagonists of 5-hydroxytryptamine on venomotor receptors. In: Critchley M, Friedman AP, Gorini S, Sicuteri F (eds) Advances in neurology. Raven, New York, pp 321–324Google Scholar
  2. Adlig WH (1984) Investigation of the venoconstrictor effect of 8’hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol 26:239–242CrossRefGoogle Scholar
  3. Ala-Hurula V, Myllylä V, Hokkanen E (1982) Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations. Cephalalgia 2:189–195PubMedCrossRefGoogle Scholar
  4. Andersson PG (1975) Ergotamine headache. Headache 15:118–121PubMedCrossRefGoogle Scholar
  5. Babayan EA, Lepakhin VK, Rudenko GM (1980) Opioid analgesics and narcotic antagonists. In: Dukes MNG (ed) Meyler’s side effects of drugs. Excerpta Medica, Amsterdam, pp 102–122Google Scholar
  6. Beaver WT (1981) Aspirin and acetaminophen as constituents of analgesic combinations. Arch Intern Med 141:293–300PubMedCrossRefGoogle Scholar
  7. Bruce M, Scott N, Lader M, Marks V (1986) The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects. Br J Clin Pharmacol 22:81–87PubMedGoogle Scholar
  8. Dichgans J, Diener HC, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 109:369–373PubMedCrossRefGoogle Scholar
  9. Gibson T, Zaphiropoulos G, Grove J, Widdop B, Berry D (1975) Kinetics of salicylate metabolism Br J Clin Pharmacol 2:233Google Scholar
  10. Henry P, Dartigues JF, Benetier MP, Lucas J, Duplan B, Jogeix M, Orgogozo JM (1985) Ergotamine-and analgesic-induced headaches. In: Rose FC (ed) Migraine. Proc 5th Int Migraine Symp London 1984. Karger, Basel, pp 197–205Google Scholar
  11. Horton BT, Peters GA (1963) Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 3:214–226CrossRefGoogle Scholar
  12. Isler H (1982) Migraine treatment as a cause of chronic migraine. In: Rose FC (ed) Advances in migraine research and therapy. Raven, New York, pp 159–164Google Scholar
  13. Kudrow L (1982) Paradoxical effects of frequent analgesic use. In: Critchley M, Friedman AP, Gorini S, Sicuteri F (eds) Advances in neurology, vol 33. Raven, New york, 335–341Google Scholar
  14. Langemark M, Olesen J (1984) Drug abuse in migraine patients. Pain 19:81–86PubMedCrossRefGoogle Scholar
  15. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A (1984) Caffeine as an analgesic adjuvant. JAMA 251:1711–1718PubMedCrossRefGoogle Scholar
  16. Linblad B, Abisch E, Bergqvist D (1983) The pharmacokinetics of subcutaneous dihydroergotamine with and without dextran 70 infusion. Eur J Clin Pharmacol 24:813–818CrossRefGoogle Scholar
  17. Lippman CW (1955) Characteristic headache resulting from prolonged use of ergot derivatives. J Nery Ment Dis 121:270–273CrossRefGoogle Scholar
  18. Mathew RJ, Wilson WH (1985) Caffeine consumption, withdrawal and cerebral blood flow, Headache 25:305–309PubMedCrossRefGoogle Scholar
  19. Mathew NT, Stubits E, Nigam MP (1982) Transformation of episodic migraine into daily chronic headache: analysis of factors. Headache 22:66–68PubMedCrossRefGoogle Scholar
  20. Maurer G, Frick W (1984) Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 26:463–470PubMedCrossRefGoogle Scholar
  21. Meadows BJ (1984) Codeine combinations in clinical practise. Curr Ther Res 35:501–510Google Scholar
  22. Müller-Schweinitzer E, Fanchamps A (1982) Effects on arterial receptors of ergot derivatives used in migraine. In: Critchley M, Friedman AP, Gorini S, Sicuteri F (eds) Advances in neurology. Raven, New York, pp 343–356Google Scholar
  23. Pincomb GA, Lovallo WR, Passay RB, Whitsett TL, Silverstein SM, Wilson MF (1985) Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol 56:119–122PubMedCrossRefGoogle Scholar
  24. Rapoport A, Weeks R, Sheftell F et al. (1985) Analgesic rebound headache: theoretical and practical implications. In: Olesen J, Tfelt-Hansen P, Jensen K (eds) Headache 1985. Proceedings of the second international headache congress. Jensen, Copenhagen, pp 448–449Google Scholar
  25. Rowsell AR, Neylan C, Wilkinson M (1973) Ergotamine induced headaches in migrainous patients. Headache 13:65–67PubMedCrossRefGoogle Scholar
  26. Saper JR (1983) Drug abuse among headache patients. In: Saper JR (ed) Headache disorders: current concepts and treatment strategies. Wright, Boston, pp 263–278Google Scholar
  27. Saxena PR (1982) Agonists and antagonists of vascular receptors. In: Critchley M, Friedman AP, Gorini S, Sicuteri F (eds) Advances in neurology. Raven, New York, pp 309–314Google Scholar
  28. Svihovec J (1980) Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG (ed) Meyler’s side effects of drugs. Excerpta Medica, Amsterdam, pp 141–164Google Scholar
  29. Tfelt-Hansen P (1986) The effect of ergotamine on the arterial system in man Acta Pharmacol Toxicol 59: [Suppl 3] 7–29Google Scholar
  30. Tfelt-Hansen P, Eickhoff JH, Olesen J (1982) Duration of the biological effect of ergotamine tartrate. In: Critchley M, Friedman AP, Gorini S, Sicuteri F (eds) Advances in neurology. Raven, New York, pp 315–319Google Scholar
  31. Wainscott G, Volans G, Wilkinson M (1974) Ergotamine induced headaches. Br Med J ii:724Google Scholar
  32. Wilkinson M (1983) Treatment of the acute migraine attack — current status. Cephalalgia 3:61–67PubMedCrossRefGoogle Scholar
  33. Woodbury DM, Fingl E (1975) Analgesic-antipyretics, anti-inflammatory agents, and drugs employed in the therapy of gout. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 325–358Google Scholar
  34. Woodcock BG, Loh W, Habedank W-D, Rietbrock N (1982) Dihydrotoxine kinetics in healthy men after intravenous and oral administration. Clin Pharmacol Ther 32:622–627PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • E. Scholz
    • 1
  • H.-C. Diener
    • 1
  • S. Geiselhart
    • 1
  1. 1.Department of NeurologyUniversity of TübingenTübingenFederal Republic of Germany

Personalised recommendations